What's new

Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 12, Status: Authorised

Jun 17, 2025 - 16:25
 0
Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 12, Status: Authorised
Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 12, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Aripiprazole Zentiva, ...

Next Article

Human medicines European public assessment report (EPAR): Velsipity, etrasimod, ...

Related Posts

EMEA-003573-PIP01-23

EMEA-003573-PIP01-23

Jun 11, 2025  0

Orphan designation: 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one Treatment of pantothenate kinase-associated neurodegeneration, 19/07/2021 Withdrawn

Orphan designation: 1-(4-(6-chloropyridazin-3-yl)pipera...

Jun 10, 2025  0

Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR...

May 23, 2025  0